We support cardiovascular research
We work with top research institutes to create new, better treatments for illnesses related to the heart and vascular system.
Since 2005 we have worked with the National Cardiovascular Research Centre (CNIC) to achieve three goals: to integrate basic genetic molecular research and its application to patients, to foster young researchers and to educate society in the importance of cardiovascular health.
As part of this project a pill has been developed to group all three active principals of the medication people who have suffered infarction need to take in a single capsule (Trinomia®).
Since 2013 we have backed the initiative to create the “First report of the Spanish record of adult cardiovascular surgery”, led by the Spanish Thoracic and Cardiovascular Surgery Society, the goal of which is to set up a structure to record and analyse the results of cardiovascular surgery in Spain.
The idea of this is to analyse these results, identify the weak points in surgical processes and bring about an improvement, to reduce mortality rates and improve patients’ welfare.
Translational research in hereditary arrhythmias - Institut d'Investigació Biomèdica de Girona IdiBGi
Sudden cardiac death (SCD) affects 800,000 people a year and is one of the main causes of morbidity and mortality in the western world.
The main objective of the project, run by the IdIBGi’s Cardiovascular Genetic Centre and led by Dr Brugada, is to improve the diagnosis of hereditary heart arrhythmias and the prevention and treatment of sudden cardiac death (SCD).
On the one hand, it is intended to identify new rare genetic alterations in the genes, mosaics and non-exonic regions associated with SCD. On the other hand, it is desired to study the function of the ionic channels and their association with arrhythmogenesis using both in vitro and in vivo models.
This will enable the transfer of the research discoveries to the taking of decisions, both by the patients and by his/her family members.
Stem cells for heart regeneration. ICREC Laboratory – iCor, Heart Institute, Hospital Germans Trias i Pujol
Heart failure is the final stage of many cardiovascular illnesses and, because of its high incidence and prevalence, is one of the greatest challenges for regenerative medicine.
The development of cardiomyocytes (heart cells) from induced pluripotent stem cells (iPS) that are able to generate most tissues opens up new opportunities in this field.
ICREC, the Heart Failure and Cardiac Regeneration group coordinated by Dr. Antoni Bayés Genís, head of the Cardiology Service at the Hospital Universitari Germans Trias i Pujol, is conducting basic and clinical research in cardiac therapy with stem cells from different tissues, and in tissue engineering, developing biocompatible polymer patches.